These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 25539586)

  • 1. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
    Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
    Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
    Rank DR; Friedland HD; Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
    Taboada M; Melnick D; Iaconis JP; Sun F; Zhong NS; File TM; Llorens L; Friedland HD; Wilson D
    J Antimicrob Chemother; 2016 Apr; 71(4):862-70. PubMed ID: 26702925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP; Low DE
    Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial.
    Zhuo C; Huang Y; Liu W; Xu JF; Zhu WY; Stone GG; Yan JL; Mohamed N
    Infect Drug Resist; 2022; 15():605-617. PubMed ID: 35237053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.
    Dryden M; Zhang Y; Wilson D; Iaconis JP; Gonzalez J
    J Antimicrob Chemother; 2016 Dec; 71(12):3575-3584. PubMed ID: 27585969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
    Frampton JE
    Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
    Blumer JL; Ghonghadze T; Cannavino C; O'Neal T; Jandourek A; Friedland HD; Bradley JS
    Pediatr Infect Dis J; 2016 Jul; 35(7):760-6. PubMed ID: 27078119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
    Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
    Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
    Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
    Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley I; Thye D
    Clin Infect Dis; 2010 Dec; 51(12):1395-405. PubMed ID: 21067350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
    Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
    Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
    Li J; Das S; Zhou D; Al-Huniti N
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
    DiMondi VP; Drew RH; Chen LF
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
    Scott LJ
    Drugs; 2016 Nov; 76(17):1659-1674. PubMed ID: 27766567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
    Lodise TP; Anzueto AR; Weber DJ; Shorr AF; Yang M; Smith A; Zhao Q; Huang X; File TM
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1119-26. PubMed ID: 25487791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
    Welte T; Kantecki M; Stone GG; Hammond J
    Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.